» Articles » PMID: 24278094

Responsiveness of the QUALID to Improved Neuropsychiatric Symptoms in Patients with Alzheimer's Disease

Overview
Journal Can Geriatr J
Specialty Geriatrics
Date 2013 Nov 27
PMID 24278094
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: This study aimed to determine whether the Quality of Life in Late-Stage Dementia (QUALID) scale is responsive to changes in behaviour due to therapeutic intervention.

Method: 31 long-term care residents with moderate to severe AD and agitation/aggression entered a three-month, open-label trial of memantine 10 mg BID. The relationships between the QUALID and BPSD, global improvement, and cognition at baseline and endpoint, as well as the changes in these scales as a result of treatment, were examined.

Results: Despite a significant improvement in agitation and aggression (NPI agitation, F3,90 = 3.721, p =.014; CMAI total, F3,90 = 6.301, p =.001) and overall behaviour (NPI total, F3,90 = 4.035, p =.010), there was no significant change in QUALID score (t30 = -0.278, p =.783). The QUALID was correlated with NPI at baseline (τ = 0.270, p =.037) and endpoint (τ = 0.404, p =.002), but change scores were not correlated (τ = 0.107, p =.412).

Conclusion: While the QUALID correlates with behavioural measures at single time points, it does not appear to correlate with changes longitudinally associated with treatment.

Citing Articles

Evaluating the Impact of Music & Memory's Personalized Music and Tablet Engagement Program in Wisconsin Assisted Living Communities: Pilot Study.

Ford Ii J, Dodds D, Hyland J, Potteiger M JMIR Aging. 2019; 2(1):e11599.

PMID: 31518259 PMC: 6716484. DOI: 10.2196/11599.


Evaluating a dementia learning community: exploratory study and research implications.

Sheaff R, Sherriff I, Hennessy C BMC Health Serv Res. 2018; 18(1):83.

PMID: 29402291 PMC: 5799896. DOI: 10.1186/s12913-018-2894-3.


Identifying and Managing Pain in People with Alzheimer's Disease and Other Types of Dementia: A Systematic Review.

Husebo B, Achterberg W, Flo E CNS Drugs. 2016; 30(6):481-97.

PMID: 27240869 PMC: 4920848. DOI: 10.1007/s40263-016-0342-7.

References
1.
Weiner M, Martin-Cook K, Svetlik D, Saine K, Foster B, Fontaine C . The quality of life in late-stage dementia (QUALID) scale. J Am Med Dir Assoc. 2003; 1(3):114-6. View

2.
Dombrovski A, Mulsant B, Ferrell R, Lotrich F, Rosen J, Wallace M . Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms. Int Clin Psychopharmacol. 2009; 25(1):37-45. PMC: 2887732. DOI: 10.1097/YIC.0b013e328333ee10. View

3.
Herrmann N, Cappell J, Eryavec G, Lanctot K . Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study. CNS Drugs. 2011; 25(5):425-33. DOI: 10.2165/11588160-000000000-00000. View

4.
McShane R, Areosa Sastre A, Minakaran N . Memantine for dementia. Cochrane Database Syst Rev. 2006; (2):CD003154. DOI: 10.1002/14651858.CD003154.pub5. View

5.
Lyketsos C, Gonzales-Salvador T, Chin J, Baker A, Black B, Rabins P . A follow-up study of change in quality of life among persons with dementia residing in a long-term care facility. Int J Geriatr Psychiatry. 2003; 18(4):275-81. DOI: 10.1002/gps.796. View